Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)

ClinicalTrials.gov ID: NCT00562497

Public ClinicalTrials.gov record NCT00562497. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 9:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHD

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of Prochymal® versus placebo in combination with corticosteroids as initial therapy for acute GVHD. Corticosteroids have been the primary therapy for patients with previously untreated acute GVHD and the historical published data define an expected 35% complete response (CR) at Day +28 using this therapy.

Study identification

NCT ID
NCT00562497
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Mesoblast, Inc.
Industry
Enrollment
192 participants

Conditions and interventions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 30, 2008
Primary completion
Jul 13, 2009
Completion
May 19, 2010
Last update posted
Jan 18, 2022

2008 – 2010

United States locations

U.S. sites
45
U.S. states
22
U.S. cities
33
Facility City State ZIP Site status
University of Alabama Birmingham (UAB) Hospital Birmingham Alabama 35249
UCLA Medical Center Los Angeles California 90095
University of California Medical Center San Francisco California 94143
Rocky Mountain Cancer Center Denver Colorado 80218
University of Florida Gainesville Florida 32610
Emory University Atlanta Georgia 30322
Northside Hospital Atlanta Georgia 30342
Northwestern Center for Clinical Research Chicago Illinois 60611
Rush University Medical Center Chicago Illinois 60612
University of Chicago Hospitals Chicago Illinois 60637
Loyola University Medical Center Maywood Illinois 60153
Indiana University Cancer Center Indianapolis Indiana 46202
St. Francis Cancer Center Indianapolis Indiana 46237
University of Louisville Louisville Kentucky 40202
Tufts New England Medical Center Boston Massachusetts 02111
Massachusetts General Hospital Boston Massachusetts 02114
Dana Farber Cancer Institute Boston Massachusetts 02115
Beth Israel Deaconess Medical Center Boston Massachusetts 02215
Barbara Ann Karmanos Cancer Institute Detroit Michigan 48201
Mayo Medical Center Rochester Minnesota 55905
University of Mississippi Medical Center Jackson Mississippi 39216
Kansas City Cancer Center Lee's Summit Missouri 64064
Washington University School of Medicine St Louis Missouri 63110
Roswell Park Cancer Institute Buffalo New York 14263
Memorial Sloan Kettering Cancer Center New York New York 10021
Mount Sinai School of Medicine New York New York 10029
New York Presbyterian Hospital New York New York 10065
University of North Carolina Hospitals Chapel Hill North Carolina 27514
Duke University Health System Durham North Carolina 27705
Wake Forest University School of Medicine Winston-Salem North Carolina 27157
Jewish Hospital Cincinnati Ohio 45236
Ohio State University Columbus Ohio 43210
Penn State Milton S. Hershey Medical Center Hershey Pennsylvania 17033
Abramson Cancer Center, University of Pennsylvania Health System Philadelphia Pennsylvania 19104
Thomas Jefferson University Philadelphia Pennsylvania 19107
Western Pennsylvania Hospital Pittsburgh Pennsylvania 15224
Oncology Hematology Association Pittsburgh Pennsylvania 15232
University of Pittsburgh Cancer Centers Pittsburgh Pennsylvania 15232
Medical University of South Carolina(MUSC) Charleston South Carolina 29425
Baylor University Medical Center Dallas Texas 75246
MD Anderson Cancer Center Houston Texas 77030
Texas Transplant Institute San Antonio Texas 78229
Virginia Commonwealth University Richmond Virginia 23298
Fred Hutchinson Cancer Research Center Seattle Washington 98109
Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00562497, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 18, 2022 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00562497 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →